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concentration of the metabolite in the cancer group (p = 0.040). 
Subsequently, EBC samples were analyzed by an LC-QTOF-Mass 
Spectroscopy (MS) using a non-targeted approach. A total of 625 
compounds were detected in all EBC samples combined among 
which, four were up regulated in patients with lung cancer (T-
Test, p < 0.05). 
Conclusions: Lower concentrations of methanol (EBC), 
glycoprotein (sputum), absence of glucose in sputum identified 
through MRS and up regulation of four specific metabolites in EBC 
identified through MS in patients with known lung cancer suggest 
that MRS and MS may provide a lung cancer specific metabolic 
profile that can be used to develop a non-invasive tool to screen 
for lung cancer in high-risk population. 
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VALIDITY OF SPECIFIC GROWTH RATE IN STAGE I NON-SMALL CELL 
LUNG CANCER TREATED WITH STEREOTACTIC BODY 
RADIOTHERAPY (SBRT)  
Soha Atallah1, Graham Cook1, Robert MacRae1, Peter Cross1, 
Andrea Bezjak2, Andrew J Hope2, Jason Pantarotto1 
1The Ottawa Hospital, Radiation Oncology Division, Ottawa, ON 
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Purpose: Non-small cell lung cancer (NSCLC) frequently 
progresses during the interval between diagnosis and initiation 
of radiation therapy. We have previously demonstrated that 
tumour growth rate (GR) is an important predictor of local-
regional control and survival in early lung cancer patients treated 
with SBRT using specific growth rate (SGR) as a metric for tumour 
growth rate, and its median (0.43x10-2) as a cut off to group 
patients into high and low SGR groups. The aim of this study was 
to:  
1) validate SGR value of 0.43x10-2 as a metric for GR; and 2)
determine the influence of pre-treatment tumour SGR on 
outcomes of early stage NSCLC patients treated with SBRT at a 
second institution. 
Methods and Materials: A retrospective chart review of 160 
patients with pathologically confirmed T1-2 N0 NSCLC patients 
treated with SBRT between June 2010 and December 2012 was 
undertaken. Demographic and clinical data were collected from 
an institutional database. Time between diagnostic and 
simulation CT scans was calculated (t). Diagnostic CT was 
uploaded to Focal planning software v.4.70. Gross tumour was 
contoured on each slice using lung window to calculate Gross 
Tumour Volume (GTV1). The pre-treatment planning CT images 
were uploaded from archived files to record the pre-treatment 
GTV (GTV2). SGR was calculated using the equation: SGR = ln 
(GTV2/GTV1)/t). The SGR cut offv(0.43x10-2) from our previous 
data was used to group patients into two cohorts. Kaplan-Meier 
curves were constructed for both overall (OS) and failure-free 
survivals (FFS), and the log rank for comparison between high 
and low SGR groups. Multivariate analyses were performed using 
a Cox proportional hazard model with SGR and other relevant 
clinical factors. 
Results: Median time interval between initial diagnostic and 
planning CT scans was 87 days (range: 5-338). The median SGR 
was 0.418 x 10-2 (range -1.1x10-2; -5.1910-2). Median GTV1 was 
3.5 cm3 (range: 0.2; 51.9 cm3) and median GTV2 was 6 cm3 
(range: 0.2; 79.1 cm3). At median follow up period of 35.8 
months, the median OS was 54 months. Three years OS was 60%. 
Patients were grouped into high and low SGR using previously 
reported SGR median as a cut off (0.43x10-2). The median 
survival was 30.3 months for high SGR versus 44.6 months for low 
SGR (p = 0.02). The median FFS was 36 months for high SGR 
versus 51.9 months for low SGR groups respectively (p < 0.01). 
On univariable analysis, gender (p = < 0.01), Stage T2 (p < 0.01), 
and GTV2 (p < 0.01) were also predictive for OS and FFS. On 
multivariate analysis only male gender (p = 0.006) and GTV2 (p = 
0.04) were predictive for OS and high SGR (p = 0.01), male gender 
(p = < 0.01), and GTV2 (p = < 0.01) were independent predictors 
for poorer FFS. 
Conclusions: This analysis of an independent data set confirmed 
the validity of pre-treatment SGR. High SGR was associated with 
poorer outcome in patients with early stage NSCLC treated with 
SBRT. Further work to correlate and combine its use with 
biological markers is ongoing. 
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Purpose: The prognostic and predictive value of 18F-FDG PET 
scans performed midway through curative-intent 
chemoradiotherapy for non-small cell lung cancer (NSCLC) 
remains to be established. This study aimed to determine if mid-
treatment 18F-FDG PET parameters predicted for the outcome 
of these patients. 
Methods and Materials: Between 2008 and 2012, nine 
consecutive patients with histologically-proven, unresected 
NSCLC who were fit to undergo curative-intent 
chemoradiotherapy (CRT) were prospectively accrued for study. 
18F-FDG PET scans were performed at baseline and after 20 
fractions of CRT. Mean standardized uptake value (SUVmean), 
maximum SUV (SUVmax) and metabolic tumour volume (MTV) 
were obtained. MTVs were automatically delineated at 50% of 
SUVmax for each lesion using a dedicated software package. 
Total lesion glycolysis (TLG) was calculated as mean SUV x MTV 
(cm3). Changes in TLG (Δ TLG) and SUVmax (Δ SUVmax) from 
baseline were used to quantify early metabolic tumour 
responses. Patients were followed for a median of 16 months 
(range 5.4 – 57.1 months). Repeat FDG-PET scan scans were 
performed at one, three, and 12 months following treatment or 
if patients had symptoms suggestive of locoregional progression 
or recurrence. Overall survival (OS) and progression-free survival 
(PFS) were calculated using the Kaplan-Meier method. Log-rank 
tests were used to compare the two survival curves. 
Results: Seven patients had AJCC Stage IIIa and two patients had 
Stage IIIb NSCLC. At the time of last follow up, three patients 
were alive and without recurrent disease. A reduction in TLG (Δ 
TLG) by 75% or more was associated with longer OS (12.5 versus 
16.4 months, p = 0.048). Baseline TLG values of 414.8 or less 
were associated with longer PFS (7.2 versus 9.0 months, p = 
0.048). Baseline and Δ SUVmax values were not associated with 
OS or PFS. 
Conclusions:  Early metabolic response midway through 
radiotherapy as quantified by Δ TLG by 75% or more was 
associated with longer OS. SUVmax at baseline and mid-
treatment and Δ SUVmax were not associated with OS or PFS. 
Early identification of poor CRT responders may allow for future 
clinical trials to improve outcomes in these patients, such as dose 
escalation with an additional RT boost. Larger studies are needed 
to confirm these findings 
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RISKS OF SABR FOR EARLY-STAGE NON-SMALL CELL LUNG CANCER 
WITH CO-EXISTING INTERSTITIAL LUNG DISEASE: A SYSTEMATIC 
REVIEW OF LITERATURE  
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Purpose: Stereotactic ablative radiotherapy (SABR) is an 
effective treatment for patients with peripherally-located early-
stage non-small cell lung cancer (ES-NSCLC). Treatment-related 
toxicity for SABR is uncommon, with a Grade 5 toxicity rate of 
0.4% in medically operable patients [Onishi et al. 2015]. Growing 
evidence suggests that patients with interstitial lung disease 
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(ILD) experience a high-risk of treatment-related morbidity and 
mortality after any pulmonary radiotherapy. The purpose of this 
study is to systematically review existing literature on SABR-
related mortality and ILD-specific toxicity for patients with co-
existing ES-NSCLC and ILD. 
Methods and Materials: The MEDLINE and Embase databases 
were queried from their respective dates of inception to January 
21, 2016. A total of 3101 records were reviewed. Studies 
involving advanced stage NSCLC, non-SABR radiotherapy 
technique, guidelines, reviews, meta-analyses, 
correspondences, or pediatric populations were excluded. SABR-
related mortality was defined as any death secondary to 
radiation pneumonitis or deaths determined to be directly 
related to radiation therapy by individual study investigators. 
Treatment-related ILD-specific toxicity was defined as Grade ≥ 3 
radiation pneumonitis following SABR. Data on treatment-
related mortality and ILD-specific toxicity for surgical studies 
were also extracted for reference. Mortality and morbidity 
results were summarized with weighted means. 
Results: A total of 13 SABR studies published between 2003 and 
2015 were included in this systematic review. Ten studies were 
retrospective in design, with the others being a mixed 
retrospective/prospective observational study, a Phase I clinical 
trial and a case report. A total of 122 patients were included in 
the reports, with most studies including medically inoperable 
patients. Weighted mean for treatment-related mortality was 
15.6% after SABR in patients with co-existing ES-NSCLC and ILD. 
Treatment-related ILD-specific toxicity occurred in 25.9% of 
SABR patients. An additional 28 surgical studies were reviewed, 
which included a total of 1681 patients. From 1999 to 2015, 
medically operable patients with co-existing ES-NSCLC and ILD 
who underwent surgery experienced treatment-related mortality 
of 2.0% and ILD-specific toxicity of 11.7%. 
Conclusions: A high incidence of treatment-related mortality 
(16%) and ILD-specific toxicity (26%) was observed after SABR for 
patients with co-existing ES-NSCLC and ILD. Many SABR patients 
were medically inoperable, preventing direct comparisons with 
surgical outcomes. Patients should be cautioned about this 
increased risk of toxicity. Future studies should aim to establish 
a specific diagnosis of the type and severity of ILD prior to the 
treatment of any patient with ES-NSCLC and co-existing 
pulmonary comorbidity. 
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Purpose: Sarcopenia, a depletion of a skeletal muscle with or 
without loss of fat mass, has been studied as a prognostic factor 
in several cancers. It has been shown to be associated with 
poorer survival and worse post-operative outcomes independent 
of patients' body weight. However, it has not been used in 
routine clinical evaluation nor has its prognostic significance in 
lung cancer been evaluated. This study examined the value of 
sarcopenia as a prognostic factor in patients with locally 
advanced non-small cell lung cancers treated with radical 
radiation and chemotherapy.  
Methods and Materials: This study included all patients with 
Stage III non-small cell lung cancer treated with radical radiation 
and chemotherapy at a regional cancer centre using the Glans 
Look database between 2006 and 2012. Body composition 
analysis of planning or pre-treatment diagnostic CT scans was 
performed using Eclipse (Varian, Palo Alto, CA) per a previously 
validated and reported technique. Total skeletal muscle area 
was calculated on a single axial abdominal CT slice at the level 
of L3 vertebral body and adjusted for stature. Patients were 
classified as sarcopenic or nonsarcopenic using validated sex-
specific cut-offs of L3 skeletal muscle index (52.4 cm2/m2 for 
males and 38.5 cm2/m2 for females). Kaplan-Meier survival 
estimates and Cox proportional-hazard models were used to 
determine the impact of sarcopenia on overall survival. 
Results: A total of 106 patients (53% males, 47% females), with 
mean age 65 years (SD = 8.7) were analyzed. Mean BMI was 26.3 
kg/m2 (SD = 6.7 kg/m2). Only one patient was underweight (BMI 
< 18.5), 40% patients had normal weight and 60% of patients were 
either overweight or obese. Overall, 38.7% patients were 
sarcopenic. The prevalence of sarcopenia was 56% among 
patients with normal weight and 27% among overweight or obese 
patients. Sarcopenia was identified as an independent predictor 
of overall survival on multivariate analysis (hazard ratio 1.71; 
95% CI 1.09 – 2.72, p = 0.019). Other significant predictors for 
worse overall survival included age over 65 years and absence of 
concurrent chemotherapy. Median survival in sarcopenic patients 
was 21 months (95% CI 13 – 28 months) compared with 31 months 
(95% CI 20 – 39 months) in nonsarcopenic patients.  
Conclusions: Sarcopenia is independently associated with 
inferior survival in patients with locally advanced non-small cell 
lung cancers treated with chemoradiotherapy. It can be routinely 
assessed in clinical practice using radiation planning software. 
Sarcopenia as independent predictor for survival and toxicity 
outcomes should be included in larger prospective clinical 
studies.  
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Purpose: The management of small cell lung cancer (SCLC) with 
radiotherapy (RT) is variable, with many treatment regimens 
described in the literature. We created a survey to assess 
patterns of practice and clinical decision making in the 
management of SCLC by Canadian radiation oncologists (ROs).  
Methods and Materials: A 35-item survey was e-mailed to 
Canadian ROs. Questions investigated the role of RT, dose/timing 
of RT, target delineation, and use of prophylactic cranial 
irradiation (PCI) in limited stage (LS) and extensive stage (ES) 
SCLC.  
Results: Fifty-two eligible ROs responded. For LS-SCLC, staging 
(98%) and simulation/dosimetric (96%) CT imaging were key 
determinants of RT suitability. The two most common 
dose/fractionation schedules were 40-45 Gy/15 once daily (QD) 
(40%) and 45 Gy/30 twice daily (33%). Elective nodal irradiation 
was performed by 31% of ROs. Preferred management of clinical 
T1/2aN0 SCLC favored primary chemoradiotherapy (64%). For ES-
SCLC, consolidative thoracic RT was frequently offered (88%), 
with a preferred dose/fractionation of 30 Gy/10 QD (70%). 
Twenty-three ROs (44%) would not offer extrathoracic 
consolidative RT. After response to initial treatment, PCI was 
generally offered in both LS- (100%) and ES- (98%) SCLC. 
Performance status, baseline cognition, and pre-PCI brain 
imaging were important clinical factors assessed prior to offering 
PCI.  
Conclusions:  There are both variations and alignment in 
practice in the management of SCLC by Canadian ROs. Future 
clinical trials and national treatment guidelines may reduce 
variability in treating early-stage disease, optimizing 
dose/targeting in LS-SCLC, and defining suitability for both PCI 
and consolidative RT. 
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PROPHYLACTIC CRANIAL IRRADIATION: DOES AGE MATTER?  
Jordan Stosky, Theodora A Koulis, Elizabeth Kurien 
University of Calgary, Calgary, AB 
 
Purpose: Prophylactic cranial irradiation (PCI) has been shown 
to provide a survival benefit and decrease occurrence of brain 
metastases in patients with small cell lung cancer (SCLC). 
